ECSP22083904A - Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso - Google Patents

Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso

Info

Publication number
ECSP22083904A
ECSP22083904A ECSENADI202283904A ECDI202283904A ECSP22083904A EC SP22083904 A ECSP22083904 A EC SP22083904A EC SENADI202283904 A ECSENADI202283904 A EC SENADI202283904A EC DI202283904 A ECDI202283904 A EC DI202283904A EC SP22083904 A ECSP22083904 A EC SP22083904A
Authority
EC
Ecuador
Prior art keywords
compounds
preparation
methods
pharmaceutical compositions
pharmaceutically acceptable
Prior art date
Application number
ECSENADI202283904A
Other languages
English (en)
Inventor
Bingcan Liu
Patrick Beaulieu
Alexander Perryman
Janek Szychowski
Frédéric Vallée
Robert Papp
Jean-François Truchon
Evelyne Dietrich
Original Assignee
Repare Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repare Therapeutics Inc filed Critical Repare Therapeutics Inc
Publication of ECSP22083904A publication Critical patent/ECSP22083904A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen compuestos y sales farmacéuticamente aceptables de estos que se pueden usar en el tratamiento de sujetos que los necesitan. Los compuestos descritos en el presente documento pueden ser inhibidores de la cinasa inhibidora de cdc2 específica de treonina y tirosina (Myt1). También se describen composiciones farmacéuticas que contienen los compuestos o sales farmacéuticamente aceptables de estos y métodos para su preparación y uso.
ECSENADI202283904A 2020-04-01 2022-10-27 Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso ECSP22083904A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063003745P 2020-04-01 2020-04-01

Publications (1)

Publication Number Publication Date
ECSP22083904A true ECSP22083904A (es) 2022-11-30

Family

ID=77927736

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202283904A ECSP22083904A (es) 2020-04-01 2022-10-27 Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso

Country Status (14)

Country Link
US (1) US20230151014A1 (es)
EP (1) EP4126879A4 (es)
JP (1) JP2023521633A (es)
KR (1) KR20230011279A (es)
CN (1) CN115916783A (es)
AU (1) AU2021250744A1 (es)
BR (1) BR112022019611A2 (es)
CA (1) CA3177200A1 (es)
CO (1) CO2022015638A2 (es)
CR (1) CR20220558A (es)
EC (1) ECSP22083904A (es)
IL (1) IL296934A (es)
MX (1) MX2022012178A (es)
WO (1) WO2021195781A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021195782A1 (en) * 2020-04-01 2021-10-07 Repare Therapeutics Inc. Methods of using myt1 inhibitors
WO2022072512A1 (en) * 2020-09-30 2022-04-07 Metacrine, Inc. Hsd17b13 inhibitors and uses thereof
CN117729920A (zh) * 2021-04-07 2024-03-19 修复治疗公司 可用作myt1抑制剂的甲酰胺吡咯并吡嗪和吡啶化合物及其在治疗癌症中的用途
WO2023155892A1 (en) * 2022-02-18 2023-08-24 Insilico Medicine Ip Limited Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
WO2023155870A1 (en) * 2022-02-18 2023-08-24 Insilico Medicine Ip Limited Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
WO2023174329A1 (en) * 2022-03-15 2023-09-21 Insilico Medicine Ip Limited Heteroaromatic compounds as pkmyt1 inhibitors and use thereof
WO2023198199A1 (zh) * 2022-04-15 2023-10-19 先声再明医药有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂
WO2023220831A1 (en) * 2022-05-18 2023-11-23 Repare Therapeutics Inc. Heteroarenes, pharmaceutical compositions containing the same, and methods of using the same
WO2023249563A1 (en) * 2022-06-23 2023-12-28 Engine Biosciences Pte. Ltd. Compounds and method for pkmyt1 inhibition
WO2024012409A1 (zh) * 2022-07-12 2024-01-18 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
WO2024041440A1 (en) * 2022-08-24 2024-02-29 Danatlas Pharmaceuticals Co., Ltd. Tricyclic heterocyclic derivatives, compositions and uses thereof
WO2024048687A1 (ja) * 2022-08-31 2024-03-07 中外製薬株式会社 Ｍｙｔ１阻害剤と化学療法剤を併用する、ｒｂ１の機能低下が生じている患者のがんの治療剤及び治療方法
WO2024061343A1 (zh) * 2022-09-23 2024-03-28 先声再明医药有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂及其应用
WO2024104282A1 (zh) * 2022-11-14 2024-05-23 捷思英达控股有限公司 一种1H-吡咯并[2,3-b]吡啶衍生物、其制备方法及其在医药上的应用
WO2024109942A1 (zh) * 2022-11-25 2024-05-30 上海齐鲁制药研究中心有限公司 Pkmyt1抑制剂、制备方法、药物组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1137415A4 (en) * 1998-12-07 2002-03-20 Smithkline Beecham Corp MYT1 KINASE INHIBITORS
CO5261594A1 (es) * 2000-03-02 2003-03-31 Smithkline Beecham Corp Inhibidores de myt1 cinasa
WO2015073528A1 (en) * 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
EP3194392B1 (en) * 2014-09-15 2020-01-01 Plexxikon, Inc. Heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
MX2022012178A (es) 2022-12-08
US20230151014A1 (en) 2023-05-18
WO2021195781A1 (en) 2021-10-07
AU2021250744A1 (en) 2022-11-17
CR20220558A (es) 2022-12-12
JP2023521633A (ja) 2023-05-25
CO2022015638A2 (es) 2022-11-18
CN115916783A (zh) 2023-04-04
BR112022019611A2 (pt) 2022-11-29
KR20230011279A (ko) 2023-01-20
EP4126879A4 (en) 2024-04-10
EP4126879A1 (en) 2023-02-08
IL296934A (en) 2022-12-01
CA3177200A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
CO2022015638A2 (es) Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso
UY38221A (es) Inhibidores de proteínas ras con g12c mutantes
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
CO2021007230A2 (es) Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CL2019001674A1 (es) Inhibidores de imidazopirazina de tirosina quinasa de bruton.
CL2020002698A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
AR067505A1 (es) Derivados de pirimidinil-piridazinona
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
UY32203A (es) Amino pirimidinas y su uso en terapia
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
CL2011000489A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala
CO2019012571A2 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
CL2022002695A1 (es) Inhibidores de rip1k
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
DOP2023000145A (es) Inhibidores de cdk2 y métodos de uso de los mismos
CO2020004977A2 (es) Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa
UY38144A (es) Inhibidores de la señalización mediada por tirosina cinasa
CL2023000655A1 (es) Degradadores de helios basados en pequeñas moléculas de piperidinilo; y uso
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados